Back to search

Article

Enhancing First-Line TKI Efficacy in PD-L1-Positive EGFR-Mutated NSCLC: The Role of Antiangiogenic Agents

2024-01-25

Abstract excerpt

<h4>Background: </h4> In individuals receiving treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), those exhibiting positive PD-L1 expression might experience reduced progression-free survival (PFS). However, the effects on overall survival (OS) and the determination of efficacious treatment approaches are still not well-defined. <h4>Methods: </h4>: In our retrospective study,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
48eb825a-4f7d-5c06-aa05-3462123b2f40
DOI
10.21203/rs.3.rs-3872785/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Enhancing First-Line TKI Efficacy in PD-L1-Positive EGFR-Mutated NSCLC: The Role of Antiangiogenic AgentsDOI 10.21203/rs.3.rs-3872785/v1
Optimal Treatment Strategies for EGFR Mutant Advanced Lung Adenocarcinoma Patients with Targeted Therapy Resistance and Correlation Analysis of PD-L1 Expression with ICI EfficacySemantic proximity
Optimal treatment strategies for EGFR mutant advanced lung adenocarcinoma patients with targeted therapy resistance and correlation analysis of PD-L1 expression with ICI efficacy.Semantic proximity
Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis.Semantic proximity
Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression.Semantic proximity
Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Semantic proximity
EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study.Semantic proximity
Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs.Semantic proximity
Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study.Semantic proximity
[A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs].Semantic proximity
Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.Semantic proximity
Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation.Semantic proximity
An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti-angiogenic agents for therapy: a case reportSemantic proximity
Select a neighboring publication to make it the new centre.